MA56450A - Promédicaments de modulateurs du récepteur nmda - Google Patents

Promédicaments de modulateurs du récepteur nmda

Info

Publication number
MA56450A
MA56450A MA056450A MA56450A MA56450A MA 56450 A MA56450 A MA 56450A MA 056450 A MA056450 A MA 056450A MA 56450 A MA56450 A MA 56450A MA 56450 A MA56450 A MA 56450A
Authority
MA
Morocco
Prior art keywords
prodrugs
nmda receptor
receptor modulator
modulator
nmda
Prior art date
Application number
MA056450A
Other languages
English (en)
Inventor
Erhad Ascic
Laurent David
John Paul Kilburn
Mauro Marigo
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA56450A publication Critical patent/MA56450A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA056450A 2019-07-03 2020-07-01 Promédicaments de modulateurs du récepteur nmda MA56450A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201900822 2019-07-03

Publications (1)

Publication Number Publication Date
MA56450A true MA56450A (fr) 2022-05-11

Family

ID=71614856

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056450A MA56450A (fr) 2019-07-03 2020-07-01 Promédicaments de modulateurs du récepteur nmda

Country Status (21)

Country Link
US (2) US11358971B2 (fr)
EP (1) EP3994140A1 (fr)
JP (1) JP2022538180A (fr)
KR (1) KR20220034052A (fr)
CN (1) CN114008053A (fr)
AR (1) AR119341A1 (fr)
AU (1) AU2020299410A1 (fr)
BR (1) BR112021003983A2 (fr)
CA (1) CA3144303A1 (fr)
CL (1) CL2021003534A1 (fr)
CO (1) CO2021017154A2 (fr)
CR (1) CR20210663A (fr)
EC (1) ECSP22003599A (fr)
IL (1) IL289576A (fr)
JO (1) JOP20210332A1 (fr)
MA (1) MA56450A (fr)
MX (1) MX2021015752A (fr)
PE (1) PE20220136A1 (fr)
PH (1) PH12021553285A1 (fr)
TW (1) TW202116780A (fr)
WO (1) WO2021001420A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021000297A1 (fr) 2019-07-03 2021-01-07 Merck Sharp & Dohme Corp. Composés et leurs procédés d'utilisation en tant qu'agents antibactériens
US11466027B2 (en) 2019-07-03 2022-10-11 H. Lundbeck A/S Modulators of the NMDA receptor
WO2023177268A1 (fr) 2022-03-18 2023-09-21 주식회사 케이티 Procédé et dispositif de traitement de flux de données d'application

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026700A (en) 1989-05-16 1991-06-25 Merrell Dow Pharmaceuticals Certain quinolines and thienopyridines as excitatory amino acid antagonists
US5252581A (en) 1992-07-20 1993-10-12 Hoechst-Roussel Pharmaceuticals Inc. Substituted aminothienopyridines, pharmaceutical composition and use
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
KR100366745B1 (ko) 1994-02-08 2003-04-18 엔피에스 파마슈티칼즈, 인코포레이티드 신경 질환 및 신경 질병의 치료에 유용한 수용체-작동된 칼슘채널의 신규 부위에서 활성인 화합물
JP2002511835A (ja) 1996-06-07 2002-04-16 エヌピーエス・ファーマシウティカルズ・インコーポレイテッド 神経障害および神経病の治療に有用な受容体作動性カルシウムチャネル上の新規部位で活性な化合物
WO1998056752A1 (fr) 1997-06-11 1998-12-17 Nps Pharmaceuticals, Inc. Composes actifs sur un nouveau site des canaux calciques actives par les recepteurs servant au tratitement des troubles et des maladies neurologiques
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
CA2815002C (fr) * 2010-11-08 2019-10-22 Janssen Pharmaceuticals, Inc. Derives 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allosteriques positifs des recepteurs mglur2
CN103298810B (zh) * 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
ES2821010T3 (es) * 2015-12-09 2021-04-23 Cadent Therapeutics Inc Moduladores heteroaromáticos del receptor NMDA y usos de los mismos
CA3047403A1 (fr) * 2016-12-22 2018-06-28 Cadent Therapeutics, Inc. Modulateurs des recepteurs nmda et utilisations de ceux-ci
US11466027B2 (en) 2019-07-03 2022-10-11 H. Lundbeck A/S Modulators of the NMDA receptor

Also Published As

Publication number Publication date
PE20220136A1 (es) 2022-01-27
JOP20210332A1 (ar) 2021-12-14
JP2022538180A (ja) 2022-08-31
ECSP22003599A (es) 2022-02-25
CL2021003534A1 (es) 2022-08-19
US11358971B2 (en) 2022-06-14
IL289576A (en) 2022-03-01
WO2021001420A1 (fr) 2021-01-07
KR20220034052A (ko) 2022-03-17
US20210047342A1 (en) 2021-02-18
CR20210663A (es) 2022-02-22
CN114008053A (zh) 2022-02-01
US20220213117A1 (en) 2022-07-07
AR119341A1 (es) 2021-12-09
TW202116780A (zh) 2021-05-01
AU2020299410A1 (en) 2022-02-03
CO2021017154A2 (es) 2022-01-17
CA3144303A1 (fr) 2021-01-07
PH12021553285A1 (en) 2022-08-01
BR112021003983A2 (pt) 2022-03-15
MX2021015752A (es) 2022-01-27
EP3994140A1 (fr) 2022-05-11

Similar Documents

Publication Publication Date Title
IL280476A (en) Aerosol generating substrate
IL280499A (en) Aerosol generating substrate
IL286120A (en) Aerosol-generating device
IL280456A (en) Aerosol generating substrate
DK3743406T3 (da) Tmem16a modulatorer
IL304460A (en) Estrogen receptor-modulating compounds
EP3595486A4 (fr) Ensemble de support réglable pour un harnais
EP4054445C0 (fr) Appareil endovasculaire
HUE062866T2 (hu) TREX-1 modulátorok
EP3932840A4 (fr) Dispositif de formation d'image
PL3956328T3 (pl) Stałe postaci modulatora receptora toll-podobnego
EP3801553A4 (fr) Promédicaments de fulvestrant
EP4041418C0 (fr) Pedalier d'exercice
EP3956329C0 (fr) Formes solides d'un modulateur de récepteur de type toll
HUE047761T2 (hu) Ösztrogén receptor modulátorok
GB201813470D0 (en) A drumstick
EP3936028A4 (fr) Dispositif de génération d'image
IL285074A (en) Gpr35 modulators
IL289576A (en) products of nmda receptor modulators
EP4061376A4 (fr) Promédicaments de fulvestrant
MA56444A (fr) MODULATEURS DU RÉCEPTEUR ALPHA DES OESTROGÈNES (ERRalpha)
EP3927330A4 (fr) Modulateurs du récepteur nurr1
IL289575A (en) nmda receptor modulators
DK3581572T3 (da) Adenosin-A3-receptormodulatorer
EP3942038A4 (fr) Modulateurs de tdp-43